Year All202620252024202320222021202020192018201720162015201420132012201120102007 12.11.20 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass , Dec. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More 12.09.20 Syndax Announces Pricing of Public Offering of Common Stock WALTHAM, Mass. , Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of Read More 12.07.20 Syndax Announces Proposed Public Offering of Common Stock WALTHAM, Mass. , Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other Read More 12.06.20 Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD - Data featured during oral session at the 62nd ASH Annual Meeting demonstrate deep, durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents - - Enrollment in pivotal AGAVE-201 trial on track to start by year-end - - Company to host conference call Read More 11.30.20 Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts WALTHAM, Mass. , Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring Read More 11.11.20 Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference WALTHAM, Mass. , Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 11.04.20 Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting - Response rate of ~60% observed in patients following a median of five prior lines of treatment - - Company to host conference call and webcast following oral presentation on Sunday, December 6, 2020 - WALTHAM, Mass. , Nov. 4, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. Read More 11.02.20 Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update - Presentation of Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for early 2021 - - Company provides update on axatilimab development plan in cGVHD following recent FDA interactions; expects to commence pivotal trial by year-end - - Data from Phase 1 trial Read More 10.26.20 Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020 WALTHAM, Mass. , Oct. 26, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2020 financial Read More 09.02.20 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Sept. 2, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More 08.06.20 Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update -- Emerging data for SNDX-5613 support several protocol enhancements to AUGMENT-101 to expand enrollment to pediatric patients and focus exclusively on patients with MLL-r and NPM1 mutant acute leukemias -- -- Recommended Phase 2 dose for AUGMENT-101 anticipated by year end; full Phase 1 data Read More 08.03.20 Syndax Announces Participation in BTIG Virtual Biotechnology Conference WALTHAM, Mass. , Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate Read More
12.11.20 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass , Dec. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More
12.09.20 Syndax Announces Pricing of Public Offering of Common Stock WALTHAM, Mass. , Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of Read More
12.07.20 Syndax Announces Proposed Public Offering of Common Stock WALTHAM, Mass. , Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other Read More
12.06.20 Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD - Data featured during oral session at the 62nd ASH Annual Meeting demonstrate deep, durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents - - Enrollment in pivotal AGAVE-201 trial on track to start by year-end - - Company to host conference call Read More
11.30.20 Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts WALTHAM, Mass. , Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring Read More
11.11.20 Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference WALTHAM, Mass. , Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
11.04.20 Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting - Response rate of ~60% observed in patients following a median of five prior lines of treatment - - Company to host conference call and webcast following oral presentation on Sunday, December 6, 2020 - WALTHAM, Mass. , Nov. 4, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. Read More
11.02.20 Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update - Presentation of Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for early 2021 - - Company provides update on axatilimab development plan in cGVHD following recent FDA interactions; expects to commence pivotal trial by year-end - - Data from Phase 1 trial Read More
10.26.20 Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020 WALTHAM, Mass. , Oct. 26, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2020 financial Read More
09.02.20 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Sept. 2, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More
08.06.20 Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update -- Emerging data for SNDX-5613 support several protocol enhancements to AUGMENT-101 to expand enrollment to pediatric patients and focus exclusively on patients with MLL-r and NPM1 mutant acute leukemias -- -- Recommended Phase 2 dose for AUGMENT-101 anticipated by year end; full Phase 1 data Read More
08.03.20 Syndax Announces Participation in BTIG Virtual Biotechnology Conference WALTHAM, Mass. , Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate Read More